ARDX Ardelyx, Inc.

+1  (5%)
Previous Close 12.05
Open 12.10
Price To book 2.95
Market Cap 596.32M
Shares 47,327,000
Volume 90,081
Short Ratio 4.27
Av. Daily Volume 213,182

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2H 2017.
Tenapanor (T3MPO-2)
Constipation-predominant irritable bowel syndrome (IBS-C)
Onset of action trial data due 3Q 2017.
Phase 3 trial initiation announced January 3, 2017.
Phase 3 released February 15, 2017 - primary endpoint met. Second Phase 3 trial to be initiated mid-2017.
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3 data due 2Q 2017.
Tenapanor (T3MPO-1)
Constipation-predominant irritable bowel syndrome (IBS-C)

Latest News

  1. Ardelyx To Present at Upcoming Spring Medical Meetings
  2. Adaptimmune Broadens Executive Team
  3. Ardelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference
  4. Wedbush Has A New Best Idea For 2017: Ardelyx
  5. Ardelyx, Inc. :ARDX-US: Earnings Analysis: Q4, 2016 By the Numbers
  6. Ardelyx reports 4Q loss
  7. Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results
  8. Blog Coverage Ardelyx Reports Positive Data for the Treatment for Hyperphosphatemia in Patients with End-Stage Renal disease
  9. Here’s What The Latest Ardelyx Inc (ARDX) Data Means For The Company Going Forward
  10. Ardelyx Says Tenapanor Did Well In Phase 3 Study
  11. Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.
  12. Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
  13. Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia
  14. Ardelyx Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference
  15. Is Ardelyx Inc (ARDX) A Good Stock To Buy Right Now?
  16. Ardelyx, Inc. :ARDX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
  17. Edited Transcript of ARDX earnings conference call or presentation 7-Nov-16 9:05pm GMT
  18. Ardelyx (ARDX) Worth Watching: Stock Rises 6.1% in Session